PT  - JOURNAL ARTICLE
AU  - Hoyle, Brian
ED  - King, Talmadge E.
TI  - Phase 3 Trial Confirms Benefits of Pirfenidone for IPF
DP  - 2014 Sep 01
TA  - MD Conference Express
PG  - 11--12
VI  - 14
IP  - 11
4099  - http://mdc.sagepub.com/content/14/11/11.2.short
4100  - http://mdc.sagepub.com/content/14/11/11.2.full
AB  - The Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis trial [ASCEND; King TE et al. N Engl J Med 2014] was a Phase 3, multinational, double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. This trial discusses findings.